| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a1dbec77e0f48c9ef56baa2ea3689287 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-335
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-56
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-565
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-704
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7048
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-565
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-127
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-475
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7135
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-337
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-335
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06 |
| filingDate |
2001-02-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f0c6440f673c0a96671d9bc3f145bc71
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_310371c7de1dfc40e249e25cf31c8f3e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cbef45155612ee6deda088452b0af1e6 |
| publicationDate |
2005-01-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
NZ-521061-A |
| titleOfInvention |
Use of estramustine phosphate co-administered with a taxane for treatment of cancer |
| abstract |
Described is the use of estramustine phosphate and its metabolites estramustine and estromustine to potentiate the therapeutic efficacy of taxanes by both improving their pharmacokinetic and pharmacodynamic profile through the inhibition of (CYP)2C8 and (CYP)3A4 enzymes, both responsible for the metabolism of the taxanes. Also described are formulations of estramustine phosphate and metabolites, and combinations of the latter with taxanes for a treatment comprising them as a combined therapy. |
| priorityDate |
2000-02-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |